132 studies found for:    Open Studies | "Bile Duct Diseases"
Show Display Options
Rank Status Study
21 Available SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury
Conditions: Cholestasis;   Growth Failure
Intervention: Drug: SMOFlipid
22 Recruiting B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
Conditions: Fatigue;   Primary Biliary Cirrhosis
Interventions: Biological: Rituximab;   Other: Placebo
23 Not yet recruiting Compassionate Use of Omegaven in Children
Conditions: Total Parenteral Nutrition-induced Cholestasis;   Cholestasis;   Short Bowel Syndrome;   Gastroschisis;   Intestinal Atresia;   Infant, Premature, Diseases;   Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven
24 Recruiting IBAT Inhibitor A4250 for Cholestatic Pruritus
Condition: Biliary Cirrhosis, Primary
Intervention: Drug: A4250
25 Not yet recruiting Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
Condition: Cholestasis
Intervention: Drug: Intralipid 20% I.V. Fat Emulsion
26 Not yet recruiting Radiological Investigation of Bile Duct Obstruction
Condition: Gallstone Disease
Interventions: Procedure: Cholecystectomy and intraoperative cholangiography;   Procedure: Magnet resonance cholangio-pancreaticography;   Device: magnet resonance imaging;   Device: catheter
27 Not yet recruiting Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Conditions: Liver Cancer;   Anxiety Disorder;   Depression;   Small Cell Lung Cancer;   Extrahepatic Bile Duct Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Esophageal Cancer;   Gastric Cancer;   Non-small Cell Lung Cancer
Interventions: Behavioral: Early palliative care;   Other: Standard oncology care
28 Recruiting Omegaven® as Parenteral Nutrition
Condition: Cholestasis
Intervention: Drug: Omegaven
29 Not yet recruiting An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
Condition: Primary Biliary Cirrhosis
Intervention: Drug: LUM001
30 Recruiting Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis
Condition: Liver Cirrhosis, Biliary
Interventions: Drug: Obeticholic Acid (OCA);   Drug: Placebo
31 Recruiting Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Conditions: Breast Cancer;   Colon Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastrointestinal Cancer;   Liver and Intrahepatic Biliary Tract Cancer;   Lung Cancer;   Metastatic Cancer;   Pancreatic Cancer;   Rectal Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: radionuclide imaging;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: Cu 64 anti-CEA monoclonal antibody M5A IV
32 Recruiting Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia
Conditions: Pancreatic Neoplasms;   Cholestasis
Interventions: Drug: nab-paclitaxel;   Drug: Gemcitabine
33 Recruiting Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
Condition: Primary Sclerosing Cholangitis
Intervention:
34 Recruiting Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis
Conditions: Primary Sclerosing Cholangitis;   Inflammatory Bowel Disease
Intervention:
35 Recruiting A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
Condition: Primary Sclerosing Cholangitis
Intervention: Drug: BTT1023
36 Recruiting Pilot Study of FFP104 Dose Escalation in PBC Subjects
Condition: Primary Biliary Cirrhosis
Intervention: Drug: FFP104
37 Recruiting Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.
Condition: Pregnancy
Intervention:
38 Recruiting Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Drug: OCA;   Drug: Placebo
39 Recruiting A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome
Condition: Alagille Syndrome
Interventions: Drug: LUM001;   Drug: Placebo
40 Recruiting Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis
Condition: Cholestasis
Intervention: Drug: Omegaven

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years